Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xinxiang
Clinical trial register · China

Clinical Trials in Xinxiang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College15 Cancer Institute and Hospital, Chinese Academy of Medical Sciences2 Pfizer2 Merck Sharp & Dohme LLC2 Ganzhou Hemay Pharmaceutical Co., Ltd2
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Xinxiang

57 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
China National Center for Cardiovascular Diseases
Phase 3
270
Beijing, Guangzhou, Shenzhen, Zhangjiakou, Xinxiang, Zhengzhou, Wuhan, Baotou
2026-11-01
Not yet open
SPH Sine Pharmaceutical Laboratories Co., Ltd.
Phase 2
150
Beijing, Chongqing, Shenzhen, Liuzhou, Xinxiang, Shiyan, Zhuzhou, Changchun
2026-10-20
Not yet open
LaNova Medicines Limited
Phase 1/2
90
Beijing, Xinxiang, Shiyan, Changsha, Liaocheng, Shanghai, Wenzhou
2026-10-19
Not yet open
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Not yet open
Mun Fei Yam
Not applicable
80
Xinxiang
2026-09-01
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
42
Beijing, Xinxiang, Nanjing, Nanchang, Changchun, Jinan, Taiyuan, Tianjin
2026-08-15
Recruiting
Bristol-Myers Squibb
Phase 2
254
Beijing, Chongqing, Guangzhou, Xinxiang, Shanghai
2026-07-27
Not yet open
Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion
NCT07670338Malignant Pleural Effusions (Mpe)
Shanghai Chest Hospital
Not applicable
308
Wuhan, Xinxiang, Weifang, Shanghai
2026-06-01
Recruiting
Mesenchymal Stem Cells in the Treatment of Burn Wounds
NCT07580755Burn Injury, Burn Patients
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
90
Xinxiang
2026-04-27
Recruiting
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
30
Xinxiang
2026-04-20
Recruiting
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
30
Xinxiang
2026-04-20
Recruiting
Screening for Biomarkers of Osteonecrosis of the Femoral Head
NCT07545616Osteonecrosis of the Femoral Head
The First Affiliated Hospital of Xinxiang Medical College
Observational
300
Xinxiang
2026-04-20
Recruiting
Screening for Biomarkers of Osteoarthritis
NCT07544823Osteoarthritis (OA)
The First Affiliated Hospital of Xinxiang Medical College
Observational
300
Xinxiang
2026-04-20
Recruiting
HUMSCs Combined With Col I to Third-Degree Burn Wound
NCT07530003Burn Wounds, Third-Degree Burn Wounds
The First Affiliated Hospital of Xinxiang Medical College
Phase 1/2
108
Xinxiang
2026-04-06
Not yet open
yilong Wang
Not applicable
86
Beijing, Kaifeng, Xinxiang, Zhengzhou, Linyi, Tianjin
2026-04-01
Recruiting
Multi-Omics Insights Into Androgenetic Alopecia
NCT07603544Androgenetic Alopecia (AGA)
The First Affiliated Hospital of Xinxiang Medical College
Observational
12
Xinxiang
2026-03-08
Recruiting
Universiti Sains Malaysia
Not applicable
120
Xinxiang
2026-03-01
Recruiting
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Chongqing, Guangzhou, Huizhou, Xinxiang
2026-02-11
Recruiting
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
141
Xinxiang
2026-01-01
Recruiting
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Recruiting
InSilico Medicine Hong Kong Limited
Phase 2
80
Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang
2025-12-10
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
24
Xinxiang
2025-12-03
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO Resistant Squamous and Nonsquamous NSCLC
Takeda
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, Ürümqi, Linhai
2025-10-08
Recruiting
VSV-02 Compassionate Use in Advanced Solid Tumors
NCT07260591Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer
The First Affiliated Hospital of Xinxiang Medical College
Phase 1
6
Xinxiang
2025-09-22
Recruiting
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Not yet open
Huashan Hospital
Observational
28,800
Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang
2025-09-01
Not yet open
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 2/3
268
Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun
2025-08-31
Not yet open
AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)
NCT07136727Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition)
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
5,000
Xinxiang
2025-08-15
Not yet open
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
NCT07124195Malignant Solid Tumors, Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs
DrugMedroxyprogesterone Acetate
The First Affiliated Hospital of Xinxiang Medical College
Phase 3
126
Xinxiang
2025-08-10
Recruiting
Chengdu CoenBiotech Co., Ltd
Phase 3
1,784
Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu
2025-08-09
Recruiting
Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects
NCT07066228Defective Composite Restorations, Bone Cysts, Bone Defect, Bone Nonunion
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
30
Xinxiang
2025-08-07
Recruiting
Celcuity Inc
Phase 3
1,180
Beijing, Quanzhou, Luoyang, Xinxiang, Zhengzhou, Changsha, Shaoyang, Nanjing
2025-07-24
Recruiting
DualityBio Inc.
Phase 2
750
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
90
Xinxiang
2025-05-02
Not yet open
Henan Cancer Hospital
Phase 2
250
Luoyang, Xinxiang, Zhengzhou
2025-01-15
Active, closed
argenx
Phase 3
631
Bengbu, Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Luoyang, Xinxiang
2025-01-15
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1
48
Harbin, Jinan, Shanghai, Xinxiang
2025-01-07
Recruiting
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Recruiting
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
By invitation
The First Affiliated Hospital of Xinxiang Medical College
Phase 1/2
29
Xinxiang
2024-10-15
Recruiting
LaNova Medicines Limited
Phase 1/2
108
Xinxiang, Liaocheng, Zibo, Shanghai
2024-10-09
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
DrugCardonilizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
Recruiting
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing, Fujian, Handan, Anyang, Xinxiang, Yinchuan, Feixian, Jining
2024-03-14
Active, closed
Beijing Chest Hospital
Phase 3
186
Beijing, Changsha, Hefei, Jiamusi, Shandong, Xi'an, Xinxiang, Shijiazhuang
2023-12-22
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
NCT06064812Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV, ER+/HER2- Breast Cancer
DrugFWD1802
Forward Pharmaceuticals Co., Ltd.
Phase 1/2
99
Hefei, Guangzhou, Huizhou, Nanning, Luoyang, Xinxiang, Zhengzhou, Wuhan
2023-09-12
Recruiting
Lin BioScience, Inc
Phase 1/2
90
Xinxiang, Jining, Tianjin
2023-07-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341Relapsed/Refractory Solid Tumors
Henan Medical University
Phase 1
20
Xinxiang
2023-01-26
Active, closed
Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT05653765Coronary Heart Disease, ST Elevation Myocardial Infarction
Henan Institute of Cardiovascular Epidemiology
Observational
2,663
Shangqiu, Xinxiang, Yongcheng, Zhengzhou, Shanghai
2022-12-20
Recruiting
Efficacy of Probiotics in Patients With IBD
NCT05652621Ulcerative Colitis, Irritable Bowel Syndrome
The First Affiliated Hospital of Xinxiang Medical College
Not applicable
200
Xinxiang
2022-07-31
Active, closed
China National Biotec Group Company Limited
Phase 3
2,898
Anyang, Jiaozuo, Luohe, Xinxiang
2021-10-22
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
663
Bengbu, Hefei, Jiangmen, Shenzhen, Shijiazhuang, Anyang, Xinxiang, Zhengzhou
2021-05-12
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Rows per page Showing 1–57 of 57
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/xinxiang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 57 of those studies with a site in Xinxiang.

How many clinical trials are recruiting in Xinxiang?

37 of the 57 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 12 have not yet opened recruitment, 7 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xinxiang), 57 studies
PhaseStudiesRecruitingShare
Not applicable13922.8%
Phase 312521.1%
Phase 29615.8%
Phase 1/28514%
Phase 17712.3%
Observational538.8%
Phase 2/3213.5%
Phase 4111.8%

Most active sponsors

Lead sponsors with the most studies (Xinxiang)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Xinxiang Medical College1512
Bristol-Myers Squibb22
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Ganzhou Hemay Pharmaceutical Co., Ltd22
LaNova Medicines Limited21
Merck Sharp & Dohme LLC21
Pfizer22
argenx10
Bambusa Therapeutics11
Beijing Chest Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.